Treatment Efficacy and Outcome of treatment of Sofosbuvir/Velpatasvir in Hepatitis C Virus Infection Among Adolescents and Young Adults

• Conditions: adolescents and young adults who have hepatitis C virus infection; Hepatitis C virus, adolescents, young adults, sofosbuvir/velpatasvir, efficacy, treatment outcome

• Registration Number: TCTR20230610001
• Lead Sponsor: Research and Developmeny Institute

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2023-06-10
• Study Completion: 2024-06-28
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Pending (Not yet recruiting)
• Sex: All
• Target Recruitment: 35

Inclusion Criteria

Aged 13-26 years
- Body weight > 30 kg
- Positive HCV RNA

Exclusion Criteria

- History of HCV infection with ever-treated
- Pregnant woman
- Uncontrollable underlying disease, e.g., HIV-infected patient who started ARV <  1 month or has an opportunistic infection
- Significant fibrosis: AST to Platelet Ratio Index (APRI) > 0.5

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
treatment efficacy at 24 months after start treatment Serum HCV RNA

Secondary Outcome Measures

Name	Time	Method
treatment outcome and adverse event at 6,12,24 weeks after start treatment by interviews